Modified Duct-to-mucosa Pancreaticojejunostomy After Pancreaticoduodenectomy
Primary Purpose
Pancreatic Fistula
Status
Unknown status
Phase
Not Applicable
Locations
China
Study Type
Interventional
Intervention
Modified one-layer duct-to-mucosa Pancreaticojejunostomy
Invagination pancreaticojejunostomy
Sponsored by
About this trial
This is an interventional prevention trial for Pancreatic Fistula
Eligibility Criteria
Inclusion Criteria:
- Written Informed consent obtained;
- Both sexes between 18 and 80 years old;
- Patients scheduled to elective open pancreaticoduodenectomy.
Exclusion Criteria:
- Patients with ASA score >=4;
- Patients who had a previous pancreatic operation;
- Patients with an immunodeficiency;
- Patients who underwent an emergency operation;
- Pregnant patients;
- Patients who was found that pancreaticoduodenectomy was not suitable。
Sites / Locations
- The First Affiliated Hospital of Nanjing Medical University
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
One-layer duct-to-mucosa Group
Invagination Group
Arm Description
Modified one-layer duct-to-mucosa pancreaticojejunostomy is used after pancreaticoduodenectomy.
Invagination pancreaticojejunostomy is used after pancreaticoduodenectomy.
Outcomes
Primary Outcome Measures
Rate of clinically relevant postoperative pancreatic fistula (POPF)
As defined by International Study Group on Pancreatic Fistula, a clinically relevant postoperative pancreatic fistula is now redefined as a drain output of any measurable volume of fluid with an amylase level >3 times the upper limit of institutional normal serum amylase activity, associated with a clinically relevant development/condition related directly to the postoperative pancreatic fistula.
Secondary Outcome Measures
Anastomosis time
Time from the beginning to the end of the pancreatic reconstruction
Delayed gastric emptying
The International Study Group for Pancreatic Surgery definition and classification of delayed gastric emptying were applied. Briefly, grade A, unable to tolerate solid oral intake by POD 7 and usually no vomiting; grade B, unable to tolerate solid oral intake by POD 14 with/without vomiting: and grade C, unable to tolerate solid oral intake by POD 21 with/without vomiting.
post-pancreatectomy hemorrhage (PPH)
The 2017 International Study Group for Pancreatic Surgery definition and classification of PPH were applied.
Chyle leak
The 2017 International Study Group for Pancreatic Surgery definition and classification of chyle leak were applied.
Overall Morbidity
Any complications that occur postoperatively. The severity of complications was graded according to the Clavien-Dindo classification.
Mortality
Patient death that occurs postoperatively
Reoperation rate
Patients who needs a surgical re-operation for any reasons during the postoperative hosptial stay. Reasons and times of reoperation are recorded.
Readmission rate
Patients that readmitted into hospital for reasons that related to complications of last pancreatic surgery.
Duration of postoperative hospital stay
Time from day of operation to day of discharge
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT03600584
Brief Title
Modified Duct-to-mucosa Pancreaticojejunostomy After Pancreaticoduodenectomy
Official Title
Modified One-layer Duct-to-mucosa Versus Invagination for Pancreaticojejunostomy After Pancreaticoduodenectomy
Study Type
Interventional
2. Study Status
Record Verification Date
July 2018
Overall Recruitment Status
Unknown status
Study Start Date
July 2018 (Anticipated)
Primary Completion Date
December 2019 (Anticipated)
Study Completion Date
March 2020 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Nanjing Medical University
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
The aim of this study is to compare surgical outcomes of modified One-layer duct-to-mucosa versus invagination pancreaticojejunostomy after pancreatoduodenectomy
Detailed Description
Duct-to-mucosa and invagination pancreaticojejunostomy are two most commonly used anastomotic techniques after pancreaticoduodenectomy, with comparable incidence rate of pancreatic fistula (PF). We modified the conventional two-layer duct-to-mucosa PJ into one-layer PJ. The aim of this study is to examine if the investigator's modified duct-to-mucosa PJ can reduce PF after PD when compared to invagination PJ.
This trial is a single-center, randomized, controlled, patient- and observer- blinded study, whose primary aim is to assess whether a modified duct-to-mucosa PJ (trial group) is superior to an invagination PJ (control group), in terms of clinically relevant PF and other complications. A total of 380 patients, who are to undergo elective PD, will be recruited and randomized intraoperatively into either of the two groups. The primary efficacy endpoint is the incident rate of clinically relevant PF. Secondary outcome measures are: entry into adjuvant therapy, mortality, surgical complications, non-surgical complications, hospital stay. Patients will be followed up for 3 months. Statistical analysis will be based on the intention-to-treat population. The duration of the entire trial is estimated to be two years.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Pancreatic Fistula
7. Study Design
Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantOutcomes Assessor
Allocation
Randomized
Enrollment
380 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
One-layer duct-to-mucosa Group
Arm Type
Experimental
Arm Description
Modified one-layer duct-to-mucosa pancreaticojejunostomy is used after pancreaticoduodenectomy.
Arm Title
Invagination Group
Arm Type
Active Comparator
Arm Description
Invagination pancreaticojejunostomy is used after pancreaticoduodenectomy.
Intervention Type
Procedure
Intervention Name(s)
Modified one-layer duct-to-mucosa Pancreaticojejunostomy
Intervention Description
After the completion of the preparation of the remnant pancreas for reconstruction was performed. Modified one-layer duct-to-mucosa Pancreaticojejunostomy was performed.
Intervention Type
Procedure
Intervention Name(s)
Invagination pancreaticojejunostomy
Intervention Description
After the completion of the preparation of the remnant pancreas for reconstruction was performed. Invagination Pancreaticojejunostomy was performed.
Primary Outcome Measure Information:
Title
Rate of clinically relevant postoperative pancreatic fistula (POPF)
Description
As defined by International Study Group on Pancreatic Fistula, a clinically relevant postoperative pancreatic fistula is now redefined as a drain output of any measurable volume of fluid with an amylase level >3 times the upper limit of institutional normal serum amylase activity, associated with a clinically relevant development/condition related directly to the postoperative pancreatic fistula.
Time Frame
Up to 60 days after Surgery
Secondary Outcome Measure Information:
Title
Anastomosis time
Description
Time from the beginning to the end of the pancreatic reconstruction
Time Frame
intraoperatively
Title
Delayed gastric emptying
Description
The International Study Group for Pancreatic Surgery definition and classification of delayed gastric emptying were applied. Briefly, grade A, unable to tolerate solid oral intake by POD 7 and usually no vomiting; grade B, unable to tolerate solid oral intake by POD 14 with/without vomiting: and grade C, unable to tolerate solid oral intake by POD 21 with/without vomiting.
Time Frame
Up to 60 day after Surgery
Title
post-pancreatectomy hemorrhage (PPH)
Description
The 2017 International Study Group for Pancreatic Surgery definition and classification of PPH were applied.
Time Frame
Up to 60 days after Surgery
Title
Chyle leak
Description
The 2017 International Study Group for Pancreatic Surgery definition and classification of chyle leak were applied.
Time Frame
Up to 60 days after Surgery
Title
Overall Morbidity
Description
Any complications that occur postoperatively. The severity of complications was graded according to the Clavien-Dindo classification.
Time Frame
Up to 60 days after Surgery
Title
Mortality
Description
Patient death that occurs postoperatively
Time Frame
Up to 90 days after Surgery
Title
Reoperation rate
Description
Patients who needs a surgical re-operation for any reasons during the postoperative hosptial stay. Reasons and times of reoperation are recorded.
Time Frame
Up to 90 days after Surgery
Title
Readmission rate
Description
Patients that readmitted into hospital for reasons that related to complications of last pancreatic surgery.
Time Frame
Up to 60 days after Surgery
Title
Duration of postoperative hospital stay
Description
Time from day of operation to day of discharge
Time Frame
Up to 90 days after Surgery
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Written Informed consent obtained;
Both sexes between 18 and 80 years old;
Patients scheduled to elective open pancreaticoduodenectomy.
Exclusion Criteria:
Patients with ASA score >=4;
Patients who had a previous pancreatic operation;
Patients with an immunodeficiency;
Patients who underwent an emergency operation;
Pregnant patients;
Patients who was found that pancreaticoduodenectomy was not suitable。
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Jishu Wei, M.D.
Phone
86-25-68136891
Email
weijishu@njmu.edu.cn
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Miao, Prof.
Organizational Affiliation
Nanjing Medical University
Official's Role
Study Director
Facility Information:
Facility Name
The First Affiliated Hospital of Nanjing Medical University
City
Nanjing
ZIP/Postal Code
210029
Country
China
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Yi Miao, PhD
Email
miaoyi@njmu.edu.cn
12. IPD Sharing Statement
Plan to Share IPD
No
Citations:
PubMed Identifier
26037262
Citation
Wei J, Liu X, Wu J, Xu W, Zhou J, Lu Z, Chen J, Guo F, Gao W, Li Q, Jiang K, Dai C, Miao Y. Modified One-layer Duct-to-mucosa Pancreaticojejunostomy Reduces Pancreatic Fistula After Pancreaticoduodenectomy. Int Surg. 2015 Jun 3. doi: 10.9738/INTSURG-D-15-00094.1. Online ahead of print.
Results Reference
background
PubMed Identifier
35289922
Citation
Hai H, Li Z, Zhang Z, Cheng Y, Liu Z, Gong J, Deng Y. Duct-to-mucosa versus other types of pancreaticojejunostomy for the prevention of postoperative pancreatic fistula following pancreaticoduodenectomy. Cochrane Database Syst Rev. 2022 Mar 15;3(3):CD013462. doi: 10.1002/14651858.CD013462.pub2.
Results Reference
derived
Learn more about this trial
Modified Duct-to-mucosa Pancreaticojejunostomy After Pancreaticoduodenectomy
We'll reach out to this number within 24 hrs